Pluri (PLUR) Stock Price, Quote, News & History

Key Statistics

Open

$0.97

Volume / Avg.

- / 24.39K

Day Range

- - -

52 Wk Range

0.85 - 4.87

Market Cap

$12.23M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

0.28%

Days to Cover

Recent Pluri Inc News

Pluri Gets $4.2M Contract To Advance Development Of Treatment For Radiation Syndrome

Pluri Inc. (NASDAQ: PLUR) has signed a three-year, $4.2 million contract with the U.S.

Nabaparna Bhattacharya

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers IM Cannabis (NASDAQ:IMCC) stock rose 108.5% to $3.63 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. Alaunos Therapeutics (NASDAQ:TCRT) shares increased

Benzinga Insights

PRO
Pluri Commences ~$3.3M Offering Of 2.229M Common Shares At $1.50 Per Share

Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri"), a biotechnology company, leveraging its proprietary three-dimensional ("3D") cell expansion platform across two principal business verticals: (i) Human

Benzinga Newsdesk

PRO
Pluri Subsidiary Ever After Foods Announces Acquisition Of Belgian Cultivated Fish Company Fishway, Secures Additional $2M Strategic Investment

Benzinga Newsdesk

PRO
Pluri Unit Cellav Health And Aesthetics Completes Cosmetic Regulatory Registration And Notification In The UK, Supporting Commercial Launch Of Regenativo+

The regulatory registration enables Cellav to commercially market its product in the UK and represents an important step in the Company's broader strategy to establish a global presence in the fast-growing

Benzinga Newsdesk

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-19.59M

Investing Cash Flow (TTM)

9.90M

Financing Cash Flow (TTM)

7.04M

Free Cash Flow (TTM)

-20.22M

Capital Expenditure (TTM)

-633.00K

Net Change in Cash (TTM)

-2.65M

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$39.13M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

9.30

PB Ratio (TTM)

Earnings Yield % (TTM)

-251.57%

Earnings Yield % (FWD)

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

-$1.83

Company Debt

Total Debt

$27.43M

LT Debt

LT Debt Issuance (TTM)

$714.00K

LT Debt Repayment (TTM)

Total Cash

$3.53M

Debt to Equity

Issuance of Debt (TTM)

$714.00K

Repayment of Debt (TTM)

Key Statistics

Open

$0.97

Volume / Avg.

- / 24.39K

Day Range

- - -

52 Wk Range

0.85 - 4.87

Market Cap

$12.23M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

0.28%

Days to Cover

About Pluri Inc

Sector

Health Care

Industry

Biotechnology

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

FAQ

How do I buy Pluri (PLUR) stock?

You can purchase shares of Pluri (NASDAQ:PLUR) through any online brokerage.

View our list of the best stock brokerages

Who are Pluri (PLUR) competitors?

Other companies in Pluri’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).

What is the forecast, or price target, for Pluri (PLUR) stock?

Pluri has a consensus price target of $12.00.

What is the current price for Pluri (PLUR)?

The stock price for Pluri (NASDAQ: PLUR) is $0.995 last updated .

Does Pluri (PLUR) pay a dividend?

There are no upcoming dividends for Pluri.

When is Pluri (NASDAQ:PLUR) reporting earnings?

Pluri does not have any upcoming earnings scheduled.

Is Pluri (PLUR) going to split?

There is no upcoming split for Pluri.

What sector and industry does Pluri (PLUR) operate in?

Pluri is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Key Statistics

Open

$0.97

Volume / Avg.

- / 24.39K

Day Range

- - -

52 Wk Range

0.85 - 4.87

Market Cap

$12.23M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

0.28%

Days to Cover

Recent Pluri Inc News

Pluri Gets $4.2M Contract To Advance Development Of Treatment For Radiation Syndrome

Pluri Inc. (NASDAQ: PLUR) has signed a three-year, $4.2 million contract with the U.S.

Nabaparna Bhattacharya

12 Health Care Stocks Moving In Friday's Pre-Market Session

Benzinga Insights

PRO
Pluri Commences ~$3.3M Offering Of 2.229M Common Shares At $1.50 Per Share

Benzinga Newsdesk

PRO
Pluri Subsidiary Ever After Foods Announces Acquisition Of Belgian Cultivated Fish Company Fishway, Secures Additional $2M Strategic Investment

Benzinga Newsdesk

PRO
Pluri Unit Cellav Health And Aesthetics Completes Cosmetic Regulatory Registration And Notification In The UK, Supporting Commercial Launch Of Regenativo+

Benzinga Newsdesk

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-19.59M

Investing Cash Flow (TTM)

9.90M

Financing Cash Flow (TTM)

7.04M

Free Cash Flow (TTM)

-20.22M

Capital Expenditure (TTM)

-633.00K

Net Change in Cash (TTM)

-2.65M

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$39.13M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

9.30

PB Ratio (TTM)

Earnings Yield % (TTM)

-251.57%

Earnings Yield % (FWD)

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

-$1.83

Company Debt

Total Debt

$27.43M

LT Debt

LT Debt Issuance (TTM)

$714.00K

LT Debt Repayment (TTM)

Total Cash

$3.53M

Debt to Equity

Issuance of Debt (TTM)

$714.00K

Repayment of Debt (TTM)

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

FAQ

How do I buy Pluri (PLUR) stock?

You can purchase shares of Pluri (NASDAQ:PLUR) through any online brokerage.

View our list of the best stock brokerages

Who are Pluri (PLUR) competitors?

What is the forecast, or price target, for Pluri (PLUR) stock?

Pluri has a consensus price target of $12.00.

What is the current price for Pluri (PLUR)?

The stock price for Pluri (NASDAQ: PLUR) is $0.995 last updated .

Does Pluri (PLUR) pay a dividend?

There are no upcoming dividends for Pluri.

When is Pluri (NASDAQ:PLUR) reporting earnings?

Pluri does not have any upcoming earnings scheduled.

Is Pluri (PLUR) going to split?

There is no upcoming split for Pluri.

What sector and industry does Pluri (PLUR) operate in?

Pluri is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Key Statistics

Open

$0.97

Volume / Avg.

- / 24.39K

Day Range

- - -

52 Wk Range

0.85 - 4.87

Market Cap

$12.23M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

0.28%

Days to Cover

About Pluri Inc

Sector

Health Care

Industry

Biotechnology

Pluri Inc (PLUR) Stock Price, Quote, News & History

Pluri (PLUR) Stock Price, Quote, News & History | Benzinga

Key Statistics

Recent Pluri Inc News

Pluri Gets $4.2M Contract To Advance Development Of Treatment For Radiation Syndrome

12 Health Care Stocks Moving In Friday's Pre-Market Session

PROPluri Commences ~$3.3M Offering Of 2.229M Common Shares At $1.50 Per Share

PROPluri Subsidiary Ever After Foods Announces Acquisition Of Belgian Cultivated Fish Company Fishway, Secures Additional $2M Strategic Investment

PROPluri Unit Cellav Health And Aesthetics Completes Cosmetic Regulatory Registration And Notification In The UK, Supporting Commercial Launch Of Regenativo+

Financials

Cash Flows

Analyst Rating and Forecast

Valuation Metrics

Company Debt

Key Statistics

About Pluri Inc

Edge Rankings

Stock Score Locked: Want to See it?

FAQ

How do I buy Pluri (PLUR) stock?

Who are Pluri (PLUR) competitors?

What is the forecast, or price target, for Pluri (PLUR) stock?

What is the current price for Pluri (PLUR)?

Does Pluri (PLUR) pay a dividend?

When is Pluri (NASDAQ:PLUR) reporting earnings?

Is Pluri (PLUR) going to split?

What sector and industry does Pluri (PLUR) operate in?

Key Statistics

Recent Pluri Inc News

Pluri Gets $4.2M Contract To Advance Development Of Treatment For Radiation Syndrome

12 Health Care Stocks Moving In Friday's Pre-Market Session

PROPluri Commences ~$3.3M Offering Of 2.229M Common Shares At $1.50 Per Share

PROPluri Subsidiary Ever After Foods Announces Acquisition Of Belgian Cultivated Fish Company Fishway, Secures Additional $2M Strategic Investment

PROPluri Unit Cellav Health And Aesthetics Completes Cosmetic Regulatory Registration And Notification In The UK, Supporting Commercial Launch Of Regenativo+

Financials

Cash Flows

Analyst Rating and Forecast

Valuation Metrics

Company Debt

Edge Rankings

Stock Score Locked: Want to See it?

FAQ

How do I buy Pluri (PLUR) stock?

Who are Pluri (PLUR) competitors?

What is the forecast, or price target, for Pluri (PLUR) stock?

What is the current price for Pluri (PLUR)?

Does Pluri (PLUR) pay a dividend?

When is Pluri (NASDAQ:PLUR) reporting earnings?

Is Pluri (PLUR) going to split?

What sector and industry does Pluri (PLUR) operate in?

Key Statistics

About Pluri Inc

PRO
Pluri Commences ~$3.3M Offering Of 2.229M Common Shares At $1.50 Per Share

PRO
Pluri Subsidiary Ever After Foods Announces Acquisition Of Belgian Cultivated Fish Company Fishway, Secures Additional $2M Strategic Investment

PRO
Pluri Unit Cellav Health And Aesthetics Completes Cosmetic Regulatory Registration And Notification In The UK, Supporting Commercial Launch Of Regenativo+

PRO
Pluri Commences ~$3.3M Offering Of 2.229M Common Shares At $1.50 Per Share

PRO
Pluri Subsidiary Ever After Foods Announces Acquisition Of Belgian Cultivated Fish Company Fishway, Secures Additional $2M Strategic Investment

PRO
Pluri Unit Cellav Health And Aesthetics Completes Cosmetic Regulatory Registration And Notification In The UK, Supporting Commercial Launch Of Regenativo+